{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:56:54Z","timestamp":1791475014175,"version":"4.3.4"},"reference-count":72,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL 131023"],"award-info":[{"award-number":["HL 131023"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01DK116095-01"],"award-info":[{"award-number":["U01DK116095-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DK066013"],"award-info":[{"award-number":["R01DK066013"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL127422"],"award-info":[{"award-number":["R01HL127422"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL132372-01A1"],"award-info":[{"award-number":["R01HL132372-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 DK1061022"],"award-info":[{"award-number":["U01 DK1061022"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1053\/j.ajkd.2018.06.010","type":"journal-article","created":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T10:39:38Z","timestamp":1536316778000},"page":"873-884","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"title":["Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies Report"],"prefix":"10.1053","volume":"72","author":[{"given":"Matthew R.","family":"Weir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay I.","family":"Lakkis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Jaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael V.","family":"Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly J.","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.ajkd.2018.06.010_bib1","first-page":"5","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease: summary of recommendation statements","volume":"3","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"5","key":"10.1053\/j.ajkd.2018.06.010_bib2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/kisup.2012.50","article-title":"KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease: summary of recommendation statements","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"10","key":"10.1053\/j.ajkd.2018.06.010_bib3","first-page":"CR462","article-title":"Late onset renal failure from angiotensin blockade (LORFFAB): a prospective thirty-month Mayo Health System clinic experience","volume":"11","author":"Onuigbo","year":"2005","journal-title":"Med Sci Monit"},{"issue":"7","key":"10.1053\/j.ajkd.2018.06.010_bib4","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/qjmed\/hcn039","article-title":"Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis","volume":"101","author":"Onuigbo","year":"2008","journal-title":"QJM"},{"issue":"3","key":"10.1053\/j.ajkd.2018.06.010_bib5","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/ki.2011.79","article-title":"An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function","volume":"80","author":"Holtkamp","year":"2011","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2018.06.010_bib6","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"Hou","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1053\/j.ajkd.2018.06.010_bib7","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1053\/j.ajkd.2018.06.010_bib8","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2018.06.010_bib9","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1111\/j.1523-1755.2004.09221.x","article-title":"Proteinuria predicting outcome in renal disease: nondiabetic nephropathies (REIN)","volume":"92","author":"Remuzzi","year":"2004","journal-title":"Kidney Int Suppl"},{"issue":"9136","key":"10.1053\/j.ajkd.2018.06.010_bib10","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0140-6736(98)04433-X","article-title":"Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy","volume":"352","author":"Ruggenenti","year":"1998","journal-title":"Lancet"},{"issue":"19","key":"10.1053\/j.ajkd.2018.06.010_bib11","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"issue":"12","key":"10.1053\/j.ajkd.2018.06.010_bib12","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1681\/ASN.V12122832","article-title":"ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy","volume":"12","author":"Ruggenenti","year":"2001","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"21","key":"10.1053\/j.ajkd.2018.06.010_bib13","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial","volume":"285","author":"Agodoa","year":"2001","journal-title":"JAMA"},{"issue":"12","key":"10.1053\/j.ajkd.2018.06.010_bib14","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s00125-011-2325-z","article-title":"Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study","volume":"54","author":"Imai","year":"2011","journal-title":"Diabetologia"},{"issue":"9638","key":"10.1053\/j.ajkd.2018.06.010_bib15","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2018.06.010_bib16","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1097\/00005344-199900001-00004","article-title":"Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group","volume":"33","author":"Maschio","year":"1999","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"issue":"12","key":"10.1053\/j.ajkd.2018.06.010_bib17","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1097\/01.ASN.0000146423.71226.0C","article-title":"Continuum of renoprotection\u00a0with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results","volume":"15","author":"Remuzzi","year":"2004","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2018.06.010_bib18","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1161\/CIRCULATIONAHA.110.964171","article-title":"Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies","volume":"123","author":"Tobe","year":"2011","journal-title":"Circulation"},{"issue":"20","key":"10.1053\/j.ajkd.2018.06.010_bib19","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1053\/j.ajkd.2018.06.010_bib20","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1056\/NEJMoa1402686","article-title":"Angiotensin blockade in late autosomal dominant polycystic kidney disease","volume":"371","author":"Torres","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2018.06.010_bib21","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jamainternmed.2013.12700","article-title":"Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia","volume":"174","author":"Hsu","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"5","key":"10.1053\/j.ajkd.2018.06.010_bib22","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000441684","article-title":"Mineral metabolites, angiotensin II inhibition and outcomes in advanced chronic kidney disease","volume":"42","author":"Jovanovich","year":"2015","journal-title":"Am J Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2018.06.010_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170874","article-title":"The impact of renin-angiotensin system blockade on renal outcomes and mortality in pre-dialysis patients with advanced chronic kidney disease","volume":"12","author":"Oh","year":"2017","journal-title":"PloS One"},{"issue":"5","key":"10.1053\/j.ajkd.2018.06.010_bib24","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/sj.ki.5000159","article-title":"ACE-inhibitor use and the long-term risk of renal failure in diabetes","volume":"69","author":"Suissa","year":"2006","journal-title":"Kidney Int"},{"issue":"10","key":"10.1053\/j.ajkd.2018.06.010_bib25","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/ijcp.12475","article-title":"A\u00a0randomized clinical trial to determine the effect of angiotensin inhibitors reduction on creatinine clearance and haemoglobin in heart failure patients with chronic kidney disease and anaemia","volume":"68","author":"Pita-Fern\u00e1ndez","year":"2014","journal-title":"Int J Clin Pract"},{"issue":"2","key":"10.1053\/j.ajkd.2018.06.010_bib26","first-page":"255","article-title":"Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial","volume":"31","author":"Bhandari","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"10.1053\/j.ajkd.2018.06.010_bib27","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1093\/ndt\/gfp511","article-title":"The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease","volume":"25","author":"Ahmed","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1053\/j.ajkd.2018.06.010_bib28","doi-asserted-by":"crossref","first-page":"c63","DOI":"10.1159\/000228536","article-title":"Analytical review of the evidence for renoprotection by renin-angiotensin-aldosterone system blockade in chronic kidney disease - a call for caution","volume":"113","author":"Onuigbo","year":"2009","journal-title":"Nephron Clin Pract"},{"issue":"7","key":"10.1053\/j.ajkd.2018.06.010_bib29","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/sj.ki.5001684","article-title":"ACE inhibitor use and the increased long-term risk of renal failure in diabetes","volume":"70","author":"Hamming","year":"2006","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2018.06.010_bib30","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1161\/CIRCULATIONAHA.117.031422","article-title":"Sodium\/glucose cotransporter 2 inhibitors in patients with diabetes mellitus and chronic kidney disease: turning the page","volume":"137","author":"Plutzky","year":"2018","journal-title":"Circulation"},{"issue":"18","key":"10.1053\/j.ajkd.2018.06.010_bib31","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","article-title":"Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials","volume":"273","author":"Garg","year":"1995","journal-title":"JAMA"},{"issue":"8875","key":"10.1053\/j.ajkd.2018.06.010_bib32","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators","volume":"342","year":"1993","journal-title":"Lancet"},{"issue":"5","key":"10.1053\/j.ajkd.2018.06.010_bib33","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1053\/j.ajkd.2018.06.010_bib34","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA.109.853648","article-title":"Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure","volume":"120","author":"Anand","year":"2009","journal-title":"Circulation"},{"issue":"8","key":"10.1053\/j.ajkd.2018.06.010_bib35","doi-asserted-by":"crossref","first-page":"629","DOI":"10.7326\/0003-4819-134-8-200104170-00007","article-title":"Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial","volume":"134","author":"Mann","year":"2001","journal-title":"Ann Intern Med"},{"issue":"24","key":"10.1053\/j.ajkd.2018.06.010_bib36","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1161\/01.CIR.0000149806.01354.BF","article-title":"Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study","volume":"110","author":"Tokmakova","year":"2004","journal-title":"Circulation"},{"issue":"10","key":"10.1053\/j.ajkd.2018.06.010_bib37","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1681\/ASN.2007020256","article-title":"Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study","volume":"18","author":"Perkovic","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.ajkd.2018.06.010_bib38","doi-asserted-by":"crossref","first-page":"542","DOI":"10.7326\/0003-4819-138-7-200304010-00010","article-title":"Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy","volume":"138","author":"Berl","year":"2003","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1053\/j.ajkd.2018.06.010_bib39","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.ahj.2008.01.031","article-title":"Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis","volume":"155","author":"Balamuthusamy","year":"2008","journal-title":"Am Heart J"},{"issue":"5","key":"10.1053\/j.ajkd.2018.06.010_bib40","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","article-title":"Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials","volume":"67","author":"Xie","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2018.06.010_bib41","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev.me.39.020188.001331","article-title":"Intraglomerular hypertension: implications and drug treatment","volume":"39","author":"Anderson","year":"1988","journal-title":"Annu Rev Med"},{"issue":"3","key":"10.1053\/j.ajkd.2018.06.010_bib42","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/ki.1997.111","article-title":"A\u00a0short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function","volume":"51","author":"Apperloo","year":"1997","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2018.06.010_bib43","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0272-6386(12)70174-9","article-title":"Hemodynamic theory of progressive renal disease: a 10-year update in brief review","volume":"22","author":"Neuringer","year":"1993","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2018.06.010_bib44","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1172\/JCI112528","article-title":"Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat","volume":"77","author":"Anderson","year":"1986","journal-title":"J\u00a0Clin Invest"},{"issue":"5","key":"10.1053\/j.ajkd.2018.06.010_bib45","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?","volume":"160","author":"Bakris","year":"2000","journal-title":"Arch Intern Med"},{"issue":"5 suppl 1","key":"10.1053\/j.ajkd.2018.06.010_bib46","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease","volume":"43","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2018.06.010_bib47","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000447068","article-title":"Should we STOP angiotensin converting enzyme inhibitors\/angiotensin receptor blockers in advanced kidney disease?","volume":"133","author":"Ahmed","year":"2016","journal-title":"Nephron"},{"issue":"6","key":"10.1053\/j.ajkd.2018.06.010_bib48","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1053\/j.ajkd.2005.08.018","article-title":"Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes","volume":"46","author":"Winkelmayer","year":"2005","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2018.06.010_bib49","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/ndt\/gfp547","article-title":"Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease","volume":"25","author":"Frimodt-M\u00f8ller","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"9721","key":"10.1053\/j.ajkd.2018.06.010_bib50","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(09)62100-0","article-title":"Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial","volume":"375","author":"Bakris","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"10.1053\/j.ajkd.2018.06.010_bib51","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.kint.2016.09.038","article-title":"Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes","volume":"91","author":"Clase","year":"2017","journal-title":"Kidney Int"},{"issue":"9","key":"10.1053\/j.ajkd.2018.06.010_bib52","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1681\/ASN.2017010040","article-title":"Acute declines in renal function during intensive BP lowering: implications for future ESRD risk","volume":"28","author":"Ku","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2018.06.010_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-151-1-200907070-00122","article-title":"Effect of telmisartan on renal outcomes: a randomized trial","volume":"151","author":"Mann","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ajkd.2018.06.010_bib54","doi-asserted-by":"crossref","first-page":"j791","DOI":"10.1136\/bmj.j791","article-title":"Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study","volume":"356","author":"Schmidt","year":"2017","journal-title":"BMJ"},{"issue":"6","key":"10.1053\/j.ajkd.2018.06.010_bib55","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1681\/ASN.2006121372","article-title":"Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency","volume":"18","author":"Hou","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2018.06.010_bib56","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000024416.33113.0A","article-title":"Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus:\u00a0a blood pressure-independent effect","volume":"106","author":"Viberti","year":"2002","journal-title":"Circulation"},{"issue":"12","key":"10.1053\/j.ajkd.2018.06.010_bib57","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1053\/j.ajkd.2018.06.010_bib58","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","article-title":"Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy","volume":"351","author":"Barnett","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1053\/j.ajkd.2018.06.010_bib59","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"Haller","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"7274","key":"10.1053\/j.ajkd.2018.06.010_bib60","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/bmj.321.7274.1440","article-title":"Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan and Lisinopril Microalbuminuria (CALM) study","volume":"321","author":"Mogensen","year":"2000","journal-title":"BMJ"},{"issue":"15","key":"10.1053\/j.ajkd.2018.06.010_bib61","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1053\/j.ajkd.2018.06.010_bib62","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1053\/j.ajkd.2018.06.010_bib63","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1053\/j.ajkd.2018.06.010_bib64","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/archinte.163.13.1555","article-title":"Effects of blood pressure level on progression of diabetic nephropathy: results from the\u00a0RENAAL study","volume":"163","author":"Bakris","year":"2003","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1053\/j.ajkd.2018.06.010_bib65","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00125-010-1922-6","article-title":"Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial","volume":"54","author":"Miao","year":"2011","journal-title":"Diabetologia"},{"issue":"3","key":"10.1053\/j.ajkd.2018.06.010_bib66","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2018.06.010_bib67","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","article-title":"Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"issue":"3","key":"10.1053\/j.ajkd.2018.06.010_bib68","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1411487","article-title":"Sodium zirconium cyclosilicate in hyperkalemia","volume":"372","author":"Packham","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1053\/j.ajkd.2018.06.010_bib69","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1001\/jama.2014.15688","article-title":"Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial","volume":"312","author":"Kosiborod","year":"2014","journal-title":"JAMA"},{"issue":"5","key":"10.1053\/j.ajkd.2018.06.010_bib70","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.ajkd.2003.07.015","article-title":"Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study","volume":"42","author":"Mann","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"15","key":"10.1053\/j.ajkd.2018.06.010_bib71","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group","volume":"334","author":"Maschio","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1053\/j.ajkd.2018.06.010_bib72","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1159\/000343453","article-title":"Tolerating increases in the serum creatinine following aggressive treatment of chronic kidney disease, hypertension and proteinuria: pre-renal success","volume":"36","author":"Hirsch","year":"2012","journal-title":"Am J Nephrol"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638618307960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638618307960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:12:57Z","timestamp":1759461177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638618307960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":72,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0272638618307960"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2018.06.010","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733999556.793550642","asserted-by":"object"}]},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies Report","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2018.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}